Diagnostic and Interventional Cardiology

Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET

Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle Medical also recently secured approval to affix the CE Mark on SubtlePET to begin marketing in the European Economic Area without restrictions.

December 05, 2018

Feature | EP Lab

Vagal Maneuvers With Supraventricular Tachycardia

Supraventricular tachycardia (SVT) is a common heart abnormality that presents as a fast heart rate. SVT is a generic term applied to any tachycardia originating above the ventricles and which involves atrial tissue or atrioventricular (AV) nodal tissue4. This heart rhythm disturbance can occur in healthy individuals and may include such symptoms as chest pain, palpitations, shortness of breath, sweating, feeling faint, and, rarely, unconsciousness may occur. The incidence of SVT is approximately 35 cases per 100,000 patients with a prevalence of 2.25 cases per 1,000 in the general population2.

December 05, 2018

News | Vena Cava Filters

First BTG Sentry Bioconvertible IVC Filter Implanted in U.S.

BTG plc announced the first patients outside of a clinical trial have been successfully implanted with the BTG Sentry device, a bioconvertible inferior vena cava (IVC) filter. The BTG Sentry filter is designed to provide protection from pulmonary embolism (PE) for the period of transient risk and then bioconvert to leave a patent, unobstructed IVC lumen. This eliminates the need to retrieve and addresses the typical filter-related complications associated with conventional IVC filters.

December 04, 2018

Sponsored Content

ASCEND provides the tools that not only address the unique needs of each cardiovascular subspecialty and to care for patients from infancy into their golden years, they also innovates next-generation solutions and services that empower the provider community to truly transform their cardiovascular services

Feature | Information Technology

SPONSORED CONTENT: Unveiling the Future of Cardiovascular Workflow

Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...

March 21, 2024

News | Population Health

Quest Diagnostics Joins One Brave Idea Research Initiative

Quest Diagnostics recently announced it will contribute biomarker implementation, population health analytics and a national lab platform as a pillar supporter of One Brave Idea, the research initiative cofounded by the American Heart Association (AHA) and Verily Life Sciences with significant support from AstraZeneca. The company said it hopes to advance the work to identify coronary heart disease at the earliest transition from wellness to disease.

December 04, 2018

News | Peripheral Artery Disease (PAD)

Lithotripsy Safe and Effective in Calcified Stenotic Peripheral Arteries

New results from the DISRUPT PAD II study showed no perforations, embolization, reflow or abrupt closures with the Shockwave Peripheral Intravascular Lithotripsy (IVL) System in the treatment of calcified, stenotic, peripheral arteries. Results of the non-randomized, multi-center study were published in Catheterization & Cardiovascular Interventions (CCI).

December 04, 2018

The American Heart Association (AHA) 2018 meeting news was the most popular content in cardiology, cardiac technology in November 2018

Feature | Dave Fornell, Editor

December 4, 2018 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

December 04, 2018

Sponsored Content

Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability to diagnose cardiac disease with greater accuracy and precision

Feature | Cardiac Imaging

SPONSORED CONTENT: Finding the Right Solution

Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...

March 05, 2024

News

First Patient Treated in STELLAR Atrial Fibrillation IDE Study

Johnson & Johnson Medical Devices Companies announced that Biosense Webster Inc. has enrolled and treated the first patient in its STELLAR U.S. Investigational Device Exemption (IDE) study. The study will evaluate the safety and effectiveness of Heliostar Multi-electrode Radiofrequency (RF) Balloon Ablation Catheter in treating symptomatic drug refractory recurrent paroxysmal (intermittent) atrial fibrillation (AF). Up to 640 patients will be enrolled in as many as 40 clinical sites worldwide.

November 30, 2018

News | Contrast Media

VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking

VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati Children’s research on pediatric nephrotoxic kidney injury and VigiLanz’s capabilities to commercialize a solution for acute kidney injury (AKI) in pediatric patients. Dubbed NINJA, or Nephrotoxic Injury Negated by Just-in-time Action, the solution enables real-time identification and monitoring of patients at risk for AKI due to exposure to nephrotoxic drugs.

November 30, 2018

News | Cardiac Diagnostics

Livongo Launches Applied Health Signals Product Category

Healthcare technology company Livongo recently announced the launch of its Applied Health Signals product category, with technologies that combine data science, behavior enablement and clinical impact to help people with chronic conditions stay healthy. The new category includes a voice-enabled, at-home, cellular blood pressure monitoring system, free medication incentives for eligible members, and a number of new data science capabilities and partnerships.

November 30, 2018

Sponsored Content

Blog

BLOG: Combining Local Impedance with Contact Force to Perform RF Ablation

When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...

December 11, 2023

News | Stroke

NeuroLogica and MaxQ AI Announce Distribution Agreement

Clinical diagnostics intelligence platform company MaxQ AI and Samsung NeuroLogica announced a distribution agreement to integrate MaxQ’s artificial intelligence (AI) software with Samsung NeuroLogica’s medical imaging hardware in the United States and European Union acute care marketplace. As part of this agreement, Samsung NeuroLogica will be able enhance its offerings with MaxQ’s Accipio Ix, part of MaxQ’s Accipio Insight intracranial hemorrhage platform, which supports acute care physicians by identifying patients with suspected intracranial hemorrhage, and prioritizing those patients using adult non-contrast head computed tomography (CT) imaging.

November 30, 2018

News | Womens Cardiovascular Health

Snoring Poses Greater Cardiac Risk to Women

Obstructive sleep apnea (OSA) and snoring may lead to earlier impairment of cardiac function in women than in men, according to a new study presented at the annual meeting of the Radiological Society of North America (RSNA). Moreover, the findings suggested that OSA may be vastly underdiagnosed among snorers.

November 29, 2018

News | Enterprise Imaging

Vital Showcases Enterprise Imaging Advances at RSNA 2018

Vital, a Canon Group company, will highlight the latest additions to its enterprise imaging portfolio at the 2018 Radiological Society of North America (RSNA) annual meeting, Nov. 25-30 in Chicago. In 2018, the company is also celebrating its 30th anniversary.

November 28, 2018

Sponsored Content